

60 Degrees Pharmaceuticals, Inc.

Q4 FY23 in-line. Babesiosis trials and Malaria marketing initiatives underway. Raising PT to \$1.30.

United States
Healthcare

April 9, 2024

Lucas Ward
(561) 427-7788
lward@ascendant.com

COMPANY UPDATE

Rating: BUY

Ticker: SXTB

Price: \$0.28

Target: \$1.30
From \$1.20

Q4 revenues from Arakoda were robust, EPS in-line: On April 1, SXTB reported full year FY23 results (ending December). Product revenues were \$258,000, ahead of our estimate of \$220,000, offset by lower-than-expected research grant revenues. Pro forma EPS was \$(0.13) for the quarter, versus our estimate of \$(0.14).

Q4 expenses higher than our forecasts: Operating expenses for the quarter came in at \$1.8 million, versus our estimate of \$700,000. Key items in the quarter included \$529,000 of stock compensation expense for directors, as well as legal, compliance, and IR expenses related to the company's equity raise and obligations as a public company. R&D expenses were contained at just \$100,000 for the quarter and \$692,000 for the year. For FY24, we are modeling \$4 million in SG&A and \$2.2 million in R&D.

Adjusting estimates: Lowering our FY24 EPS estimate to \$(0.61) from \$(0.44) on revenues of \$800,000. We are initiating an estimate of \$(0.41) on revenues of \$2.1 million for FY25. This compares to consensus estimates of \$(0.44) and \$(0.12) for FY24 and FY25, respectively.

North Carolina State University study will explore use of Arakoda for canine Babesiosis: On April 3, 60 Degrees announced that it will sponsor a trial of Tafenoquine for canine Babesiosis. The trial is expected to have results in 12 months and provide additional confirmation of the efficacy of Tafenoquine for Babesiosis. Though it is an off-label indication, canine Babesiosis represents an incremental market opportunity for Arakoda.

Company on track to begin Babesiosis trial in June: Following a Type C meeting with FDA in January, 60 Degrees Pharma is on track to conduct a pivotal clinical study in the US in support of a future indication for tafenoquine for treatment of hospitalized babesiosis patients. The company expects to start enrolling patients in June of 2024 and complete the trial by year-end. If all goes well, the company will file an NDA by Q3 of FY25 and receive FDA approval by Q1 of FY26.

Babesiosis represents incremental opportunity to Malaria: In the US, there are at least 47,000 cases of Babesiosis, a tick-borne disease that co-infects with Lyme Disease in 10% of reported Lyme Disease cases. Thousands of people end up hospitalized each year. 60 Degrees hopes to establish tafenoquine as an important prophylaxis and cure for the disease which can be used with existing standard of care medicine.

Company refining marketing strategy for Malaria: With the hiring of Kristen Landon as Chief Commercial Officer, 60 Degrees has taken an important step towards developing an active marketing campaign for Arakoda for Malaria. Currently the company is completing a survey of prescribers to understand market demand and elasticity.

Balance sheet strengthened with public offering: The company exited December with \$2.1 million of cash on the balance sheet, (70% of its market cap). On January 31, SXTB closed a new offering of stock and warrants which should add an estimated \$1.9 million to the company's cash reserve, helping to fund the planned clinical trial of Tafenoquine for hospitalized Babesiosis patients. We estimate SXTB will likely need to raise money again by Q3 FY24.

Raising 12-month price target: Given incremental business progress, we are raising our price target to \$1.30 (from \$1.20). This is based on a NPV analysis, representing 3.7x upside from the current share price. We believe this valuation appropriately balances out the company's high risks with the company's high growth prospects and large upside opportunities.

Company Description

Based in Washington, DC, 60 Degrees Pharmaceuticals, Inc. is a drug company specializing in therapeutics for major infectious diseases.

Stock Data

Exchange:	NasdaqCM
52-week Range:	\$0.26-8.65
Shares Outstanding (million):	11.1
Market cap (\$million):	\$3.1
EV (\$million):	\$1.0
Debt (\$million):	\$0
Cash (\$million):	\$2.1
Avg. Daily Trading Vol (\$ millions):	\$0.1
Float (million shares):	4.1
Short Interest (million shares):	0.07
Dividend, annual (yield):	NA

Revenues (US\$ million)

	2024E (Cur.)	2024E (Old.)	2025E (Cur.)	2025E (Old.)
Q1 Mar	0.0E		0.3E	
Q2 Jun	0.2E		0.4E	
Q3 Sep	0.2E		0.6E	
Q4 Dec	0.3E		0.8E	
Total	0.8E		2.1E	
EV/Rev	1.2x		0.5x	

Earnings per Share (pro forma)

	2024E (Cur.)	2024E (Old.)	2025E (Cur.)	2025E (Old.)
Q1 Mar	(0.22)E	(0.14)E	(0.11)E	
Q2 Jun	(0.14)E	(0.11)E	(0.10)E	
Q3 Sep	(0.15)E	(0.11)E	(0.08)E	
Q4 Dec	(0.12)E	(0.09)E	(0.08)E	
Total	\$(0.61)E	\$(0.44)E	\$(0.41)E	
PE	NA		NA	

Important Disclosures

Ascendant Capital Markets LLC seeks to do business with companies covered by its research team. Consequently, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making an investment decision.

For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report, beginning on page 11.

Exhibit 1: 60 Degrees Pharmaceuticals Investment Highlights

Investment Highlights

- **ARAKODA – a long-acting, potentially broad-spectrum, anti-infective already FDA-approved for malaria prevention and commercially available in the U.S.**
 - Safe, long acting, mechanistically differentiated antimalarial approved by FDA
 - Discovered by US Army and successfully brought to market by 60P
 - 1,100+ patient exposures in 8+ published clinical trials, weekly dosing for up to one year
 - Commercially available in U.S. via network of major national distributors
 - Existing commercial/regulatory infrastructure expected to facilitate cost-effective pathway to new/expanded indications following targeted clinical trial and label changes
- **Arakoda Regimen of Tafenoquine – Research agenda involving COVID-19 and other diseases**
 - Malaria, COVID-19, fungal, tick-borne illness of interest to the Company affect millions and are associated with a potentially multi-billion-dollar unmet medical need
 - Company has strong IP for malaria, COVID-19, and other indications
 - Accelerated clinical recovery from COVID-19 symptoms suggested results from 2021 double-blind, placebo-controlled, randomized Phase II study
 - 2023: Launch of ACLR8-LR, a Phase 2b study in low-risk COVID-19 patients
 - 2024: Second COVID-19 clinical planned
- **Experienced management team and Board**
 - Team has together led/managed four clinical trials
 - Collectively led multiple pharmaceutical product approvals/product launches
 - Collectively led/provided guidance on 20+ public & private entities
 - Participated in/led multiple public listings

Source: Company Reports

Exhibit 2: Overview of ARAKODA

Overview

The team at 60 Degrees Pharmaceuticals, a growth-oriented biotech company, specializes in developing and commercializing new therapies used in preventing and treating serious infectious diseases.

Cutting-edge biological science and applied research form the foundation of our highly-focused, advanced clinical strategy.


In 2018, 60 Degrees Pharmaceuticals was awarded U.S. regulatory approval of ARAKODA® (tafenoquine), a malaria preventative treatment.

COVID-19, fungal, tick-borne, and other serious viral diseases are targets in our current product development pipeline, given the relevant unmet needs we perceive in the marketplace.




Source: Company Reports

Exhibit 3: 60 Degrees Pharmaceuticals Product Portfolio



Source: Company Reports

Exhibit 4: 60 Degrees Pharmaceuticals Key Milestones



Source: Company Reports

Exhibit 5: 60 Degrees Pharmaceuticals Supply Chain



Source: Company Reports

Exhibit 6: 60 Degrees Pharmaceuticals Intellectual Property

Intellectual Property & Licensing

60 Degrees Pharmaceuticals has freedom to operate

- **U.S. Arakoda Patents (2 issued/6 in progress)**
 - Tafenoquine for malaria prevention patent family: Earliest expiration December 2034
 - Tafenoquine for lung Infections/COVID Treatment: Earliest expiration March 2041
- **U.S. Celgosivir Patents**
 - Dengue/RSV (4 issued/2 in progress)
 - COVID-19 licensed from FSU (1 issued/1 in progress)
- **International Patents**
 - 6/2 for Celgosivir issued/in progress, 1/8 for tafenoquine issued/in progress
- **Clinical, non-clinical and manufacturing information:**
 - Worldwide rights for all indications [except P. vivax malaria] licensed from US Army

Existing License & Distribution Agreements [Malaria]

Territory	Partner
Europe	Scandinavian Biopharma
Australia, NZ, Pacific Islands	Bioelect
Canada, Latin America, Israel, Russia	Knight Therapeutics

Source: Company Reports

Exhibit 7: 60 Degrees Pharmaceuticals Officers and Directors

Officers & Directors



Geoffrey Dow MBA PHD, CEO & Chairman

- Affiliations: WRAIR, USAMMDA
- Founded & led 60P from 2010-2023
- Industry Project Leader on Arakoda NDA



Ty Miller, CFO

- CPA
- CFO since 2014
- Over 20 years in Private Practice



Bryan Smith MD, Chief Medical Officer

- Retired US Army Colonel/30+ years experience
- Two successful NDAs as a Chief Medical Officer
- Medical affairs/regulatory expert in GxP environment



Jenny Herz, Director of 60P Australia since 2013

- 20 years commercial experience in pharma (Sanofi, AZ)
- International launch experience with multiple products
- Co-founder of Biointelect and Biocellect
- Board experience in public, private, NFP sectors



Cheryl Xu, Director

- First PhRMA representative to China
- Senior Advisor to multinationals (market access and expansion)
- Project Leader (multiple public health projects)



Stephen Toovey MD, PHD Director

- Affiliations: Roche, Pegasus Research, WHO Collaborating Centre for Vaccines and Travel Medicine, London, UK
- Tropical medicine subject matter expert
- Respiratory virus subject matter expert



Paul Field, Director

- Affiliations: GARDP, Immunexus, Marinova
- 30 years global biotech business development experience
- Previously investment specialist at Austrade, focused on tropical medicine and NTDs



Charles Allen, Director

- Affiliations: BTCS & GBV
- CEO & Chairman of NASDAQ listed company
- Managing Director, several boutique investment banks
- Broad business experience across multiple sectors

Source: Company Reports

Exhibit 8: ARAKODA Product Factsheet

About ARAKODA® [tafenoquine succinate]

- Developed by US Army as a prophylactic antimalarial (through 2013)
- 60P and USAMMDA formed a partnership in 2014:
 - FDA approval in 2018 [for malaria prevention]
 - Commercially available in U.S. from Q3 2019
- Dosing & Duration of Use
 - Load: 200 mg/day x 3 days
 - Maintenance: 200 mg once per week
- Safety Profile
 - 8 published clinical studies involving > 1,100 patients
 - Overall adverse event rate of tafenoquine 200 mg weekly for 52 weeks is comparable to placebo.
 - G6PD screening required prior to use
 - See paper in *Travel Medicine & Infectious Disease* [Long-term safety of the tafenoquine antimalarial chemoprophylaxis regimen: A 12-month, randomized, double-blind, placebo-controlled trial - ScienceDirect]



Source: Company Reports

Exhibit 9: Tafenoquine Use in Multiple Indications

Tafenoquine – Potential Use in Multiple Indications

A – Malaria¹

Legend: Mean tafenoquine (solid line with squares), Mean placebo (dashed line with circles), Individual subject tafenoquine (solid lines), Individual subject placebo (dashed lines).

C – Yeasts & Fungi³

Species/Strain	Tafenoquine MIC [µg/mL]		
	50% inhibition	Complete suppression	Fluconazole MIC [µg/mL]
<i>Candida parapsilosis</i> ATCC 22019	4	4	1
<i>C. azouyi</i> ATCC 6258	4	4	32
<i>C. albicans</i> SC5314	8	8	0.5
<i>C. albicans</i> ATCC 90028	4	4	0.25
<i>C. albicans</i> CA1	4	4	> 64
<i>C. azouyi</i> D17-47	4	4	> 64
<i>C. azouyi</i> D17-48	2	4	2
<i>C. azouyi</i> D17-46	4	4	> 64
<i>C. glabrata</i> 05-42	8	8	> 64
<i>C. glabrata</i> 05-761	8	8	8
<i>C. glabrata</i> CG3	8	8	32
<i>C. guilliermondii</i> Cgu11	2	2	2
<i>C. guilliermondii</i> Cgu2	2	2	2
<i>C. guilliermondii</i> Cgu3	4	4	2
<i>C. parapsilosis</i> CP1	4	4	0.5
<i>C. parapsilosis</i> CP2	4	4	0.5
<i>Cryptosporidium nayloriformans</i> CUC1597	4	4	4
<i>C. neoformans</i> H99	4	4	16
<i>C. neoformans</i> CN3	4	4	64
Average (SD)	4.5 (1.9)	4.9 (1.9)	NC

NC = Not calculated.

B – Babesiosis²

Legend: Serum (blue dots), PCR (red squares), Atovaquone (green circles), Clindamycin (yellow triangles), Quinine (purple diamonds), Atovaquone/quinine (orange stars), Tafenoquine (red crosses).

D- SARS-CoV-2/COVID-19⁴

Legend: Plasma (black), Lung (blue), Lung µ (red), EC50 (green), EC50 µ (orange), EC50 µ (yellow).

1. McCarthy et al. CID 2019;69:480-486. 2. Rogers et al CID 2022. doi: 10.1093/cid/ciac473. 3. Dow & Smith. New Microbes New Infections; doi: 10.1016/j.nmni.2022.100964. 4. U.S. Patent Application Publication No. 2021-0267963.

Source: Company Reports

Exhibit 10: 60 Degrees Pharmaceuticals use of IPO Funds

Use of IPO Funds

Item	Amount
General Corporate Purposes	\$2,411,276
Debt Repayment	\$1,925,000
Research and Development	\$3,200,000
R+D Tax Credits	(\$1,400,000)
Total*	\$6,336,276

*Represents net proceeds from the offering

Source: Company Reports

Exhibit 11: SXTP Consensus Expectations

4/7/24

	Revenue (\$ million)		EPS	
	FY2024E	FY2025E	FY2024E	FY2025E
Q1 Mar	\$0.2E		Q1 Mar	\$(0.14)E
Q2 Jun	\$0.3E		Q2 Jun	\$(0.11)E
Q3 Sep	\$0.3E		Q3 Sep	\$(0.11)E
Q4 Dec	\$0.4E		Q4 Dec	\$(0.09)E
Total	\$1.3E	\$3.8E	Total	\$(0.44)E
				\$(0.12)E

Source: Company reports, CapitalIQ, Ascendant Capital Markets Estimates

Exhibit 12: 60 Degrees Pharmaceuticals, Inc. Daily Stock Price Since IPO (July 2023)



Source: <https://bigcharts.marketwatch.com/>

FINANCIAL MODEL

60 Degrees Pharmaceuticals, Inc.

Income Statement (\$ mils)	2021	2022	Mar-23	Jun-23	Sep-23	Dec-23	2023	Mar-24	Jun-24	Sep-24	Dec-24	2024	Mar-25	Jun-25	Sep-25	Dec-25	2025
Fiscal Year End: December 31	FY-A	FY-A	Q1A	Q2A	Q3A	Q4A	FY-A	Q1E	Q2E	Q3E	Q4E	FY-E	Q1E	Q2E	Q3E	Q4E	FY-E
Research Grant Revenues (1,2)	5.2	0.29	0.0	0.0	0.1	(0.1)	0.00					0.0					0.0
Product Revenues (3)	1.1	0.19	0.0	0.06	0.05	0.126	0.254	0.1	0.2	0.2	0.3	0.8	0.3	0.4	0.6	0.8	2.1
Service Revenues	0.1	0.03					0.0					0.0					0.0
Total Revenue	6.4	0.51	0.02	0.06	0.13	0.0	0.3	0.1	0.2	0.2	0.3	0.8	0.3	0.4	0.6	0.8	2.1
Cost Of Goods Sold	0.9	0.43	0.07	0.18	0.07	0.1	0.5	0.2	0.2	0.2	0.2	0.6	0.2	0.2	0.2	0.2	0.6
Gross Profit	5.5	0.08	(0.1)	(0.1)	0.1	(0.1)	(0.2)	(0.0)	0.0	0.1	0.1	0.2	0.2	0.3	0.5	0.7	1.5
R & D Exp.	5.5	0.53	0.1	0.2	0.3	0.1	0.7	0.4	0.6	0.7	0.5	2.2	0.4	0.3	0.3	0.5	2.0
Selling General & Admin Exp.	1.1	1.30	0.8	0.5	1.3	1.7	4.2	1.0	1.0	1.0	1.0	4.0	1.0	1.0	1.0	1.0	4.0
Other Operating Expense/(Income)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Operating Expenses	6.6	1.83	0.9	0.7	1.6	1.8	4.9	1.4	1.6	1.7	1.5	6.2	1.4	1.3	1.3	1.5	6.0
Operating Income	(1.1)	(1.75)	(1.0)	(0.8)	(1.5)	(1.9)	(5.2)	(1.4)	(1.6)	(1.6)	(1.4)	(6.0)	(1.2)	(1.1)	(0.9)	(0.9)	(4.5)
Interest Expense	(3.2)	(3.99)	(1.1)	(1.1)	(0.0)	(0.0)	(2.3)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
Interest and Invest. Income																	
Total Interest and Other Income (Expense)	(3.2)	(3.99)	(1.1)	(1.1)	(0.0)	(0.0)	(2.3)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
Derivative Expense		(0.50)		(0.4)	0.0	0.0	(0.4)										
Change in Fair Value of Derivative Liabilities		(0.01)	(0.0)	0.0	0.1	(0.1)	(0.0)										
Gain on Debt Extinguishment		0.12	(0.8)	0.0	(0.4)	0.0	(1.2)										
Gain in Fair Value of Promissory Note			0.3	(1.1)	6.1	0.0	5.4										
Other (Expense)/Income	0.0	(0.04)	0.0	0.0	(0.1)	(0.0)	(0.1)										
Extra Items	0.0	(0.44)	(0.5)	(1.5)	5.7	(0.1)	3.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Earnings Before Tax	(4.3)	(6.18)	(2.6)	(3.3)	4.2	(2.0)	(3.8)	(1.4)	(1.6)	(1.6)	(1.4)	(6.0)	(1.2)	(1.1)	(0.9)	(0.9)	(4.5)
Income Tax Expense	0.0	0.00	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net Income before Minority Interest	(4.3)	(6.18)	(2.6)	(3.3)	4.2	(2.0)	(3.8)	(1.4)	(1.6)	(1.6)	(1.4)	(6.0)	(1.2)	(1.1)	(0.9)	(0.9)	(4.5)
Unrealized Foreign Currency Translation Gain (Loss)					0.0	0.1	0.1										
Minority Int. in Earnings	(0.0)	(0.00)	0.0	(0.0)	(0.0)	(0.0)	(0.0)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Comprehensive Net Income	(4.3)	(6.17)	(2.6)	(3.3)	4.2	(2.0)	(3.7)	(1.4)	(1.6)	(1.6)	(1.4)	(6.0)	(1.2)	(1.1)	(0.9)	(0.9)	(4.5)
Cumulative dividends on Series A Preferred Stock					0.1	(0.3)	(0.2)										
Net Income to Common	(4.3)	(6.17)	(2.6)	(3.3)	4.1	(1.6)	(3.9)	(1.4)	(1.6)	(1.6)	(1.4)	(6.0)	(1.2)	(1.1)	(0.9)	(0.9)	(4.5)
Net Income Pro Forma	(4.3)	(5.74)	(2.1)	(1.9)	(1.6)	(1.5)	(7.6)	(1.4)	(1.6)	(1.6)	(1.4)	(6.0)	(1.2)	(1.1)	(0.9)	(0.9)	(4.5)
Diluted EPS	NA	(2.59)	(1.13)	(1.40)	0.77	(0.41)	(0.99)	(0.22)	(0.14)	(0.15)	(0.13)	(0.61)	(0.11)	(0.10)	(0.08)	(0.08)	(0.41)
Diluted EPS Pro Forma	NA	(2.41)	(0.91)	(0.79)	(0.31)	(0.38)	(1.91)	(0.22)	(0.14)	(0.15)	(0.13)	(0.61)	(0.11)	(0.10)	(0.08)	(0.08)	(0.41)
Weighted Avg. Diluted Shares Out.	NA	2.38	2.30	2.38	5.32	3.96	3.96	6.33	11.07	11.07	11.07	9.89	11.07	11.07	11.07	11.07	11.07

1) research revenues have historically been derived mostly from a single, awarded research grant in the amount of \$5.72 million in 2021 from the JPEO to study ARAKODA in low risk COVID-19 patients.
 2) Research revenues from the Australian Tax Authority were \$4,292 in Q1 2023 compared to \$22,239 in Q2 2022.
 3) The decrease insales was mainly due to end of a 3-year Arakoda US Army acquisition contract that involved purchasing a full lot (7,500 boxes) in 2020 and a half lot (3,750 boxes) in 2021.

Margins																	
Gross margin	87%	15%	-241%	-194%	44%	-242%	-87%	-7%	12%	32%	44%	25%	53%	63%	75%	81%	72%
R & D Exp.	87%	103%	578%	325%	208%	235%	273%	286%	353%	318%	185%	275%	125%	75%	50%	63%	94%
Selling General & Admin Exp.	18%	255%	3611%	739%	1036%	3958%	1673%	714%	588%	455%	370%	500%	313%	250%	167%	125%	189%
Operating margin	-18%	-342%	-4429%	-1258%	-1201%	-4435%	-2033%	-1007%	-929%	-741%	-511%	-750%	-384%	-263%	-142%	-106%	-211%
Net margin	-64%	-338%	-289%	-500%	266%	-109%	-75%	-101%	-99%	-97%	-93%	-97%	-89%	-82%	-66%	-57%	-75%
Y/Y % change																	
Revenue	149%																
COGS	21%	-49%	-19%	111%	-46%	18%	10%	105%	-18%	111%	3%	26%	0%	0%	0%	0%	0%
Gross Profit	198%	-99%	-170%	144%	-75%	-49%	-380%	-81%	-116%	26%	-216%	-191%	-1800%	1150%	543%	442%	660%
R & D Exp.	583%	-90%	97%	-12%	44%	107%	32%	223%	194%	165%	399%	218%	0%	-50%	-57%	0%	-9%
Selling General & Admin Exp.	-23%	17%	344%	14%	408%	264%	225%	29%	116%	-24%	-41%	-6%	0%	0%	0%	0%	0%
Total operating expenses	193%	-72%	278%	5%	257%	249%	170%	56%	140%	8%	-16%	26%	0%	-19%	-24%	0%	-3%
Operating Income	169%	56%	481%	15%	607%	165%	194%	48%	101%	7%	-27%	16%	-13%	-34%	-48%	-38%	-25%
Net income	40%	45%	185%	55%	-448%	1%	-40%	-45%	-52%	-139%	-29%	63%	-13%	-33%	-48%	-38%	-25%
EPS				54%	-252%	-49%	-62%	-80%	-90%	-119%	-70%	-38%	-50%	-33%	-48%	-38%	-33%

Source: Company reports, Ascendant Capital Markets estimates

60 Degrees Pharmaceuticals, Inc.

Balance Sheet (\$ mils)	Dec-22	Mar-23	Jun-23	Sep-23	Dec-23	Mar-24	Jun-24	Sep-24	Dec-24	Mar-25	Jun-25	Sep-25	Dec-25
Fiscal Year End: December 31	Q4A	Q1A	Q2A	Q3A	Q4A	Q1E	Q2E	Q3E	Q4E	Q1E	Q2E	Q3E	Q4E
Current Assets													
Cash And Equivalents	0.3	0.0	0.0	2.2	2.1	2.7	1.1	(0.5)	(1.9)	(3.1)	(4.2)	(5.1)	(5.9)
Accounts Receivable	0.0	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Prepaid Exp.	0.2	6.5	6.3	5.9	4.4	4.4	4.4	4.4	4.4	4.4	4.4	4.4	4.4
Deferred Offering Costs	0.1	0.1	0.2		0.0								
Inventory	0.5	0.6	0.5	0.6	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Total Current Assets	1.1	7.3	7.1	8.9	7.2	7.8	6.2	4.6	3.2	2.0	0.9	0.0	(0.8)
Property, Plant & Equipment, net	0.0	0.1	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Right of Use Asset	0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Intangible Assets	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Other Long-Term Assets					0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Total Assets	1.3	7.6	7.4	9.2	7.8	8.4	6.8	5.1	3.7	2.5	1.4	0.6	(0.3)
LIABILITIES													
Accounts Payable	0.8	0.8	1.1	0.3	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Lease Liability	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Compensation	0.3		0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Related Party Notes	0.2	0.5	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Debenture	4.3			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SBA EIDL	0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Promissory Notes at Fair Value	16.9	22.6	23.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Promissory Notes			1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Derivative Liabilities	1.1		2.1	2.2	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3
Derivative Liabilities - Related Parties	0.4		0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Current Liabilities		1.5											
Short-term Borrowings	0.2	0.5	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Curr. Port. of LT Debt	21.1	22.6	24.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Current Liabilities	23.9	25.5	28.9	2.5	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8
Deferred Compensation	0.3	0.3		0.0	0.0								
Long-Term Leases				0.0	0.0								
Debenture				0.0	0.0								
Related Party Note				0.0	0.0								
SBA EIDL	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Promissory Notes	1.1	1.2	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Long-Term Debt	1.3	1.3	1.4	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Total Liabilities	25.4	27.1	30.2	2.6	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0
Members' Capital		0.0	0.0	0.0	0.0								
Preferred Stock				9.9	9.9	9.9	9.9	9.9	9.9	9.9	9.9	9.9	9.9
Common Stock	0.0			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Additional Paid In Capital	5.2	12.4	12.4	27.2	27.5	29.5	29.5	29.5	29.5	29.5	29.5	29.5	29.5
Accumulated Other Comprehensive In	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Retained Earnings	(28.8)	(31.4)	(34.8)	(30.6)	(32.6)	(34.0)	(35.6)	(37.2)	(38.6)	(39.9)	(40.9)	(41.8)	(42.6)
Total Common Equity	(23.6)	(19.0)	(22.3)	6.6	4.9	5.4	3.9	2.2	0.8	(0.4)	(1.5)	(2.3)	(3.2)
Minority Interest	(0.6)	(0.6)	(0.6)	(0.0)	(0.1)	(0.1)	(0.1)	(0.1)	(0.1)	(0.1)	(0.1)	(0.1)	(0.1)
Total Equity	(24.1)	(19.5)	(22.9)	6.5	4.8	5.4	3.8	2.1	0.8	(0.5)	(1.5)	(2.4)	(3.3)
Total Liabilities And Equity	1.3	7.6	7.4	9.2	7.8	8.4	6.8	5.1	3.7	2.5	1.4	0.6	(0.3)
	Dec-22	Mar-23	Jun-23	Sep-23	Dec-23	Mar-24	Jun-24	Sep-24	Dec-24	Mar-25	Jun-25	Sep-25	Dec-25
	Q4A	Q1A	Q2A	Q3A	Q4A	Q1E	Q2E	Q3E	Q4E	Q1E	Q2E	Q3E	Q4E
Balance Sheet Drivers													
Accounts Receivable (Days)	(53)	347	180	98	488	149	122	95	77	65	52	35	26
Inventory (Days)	(601)	2610	669	425	982	300	247	191	155	131	105	70	52
Accounts Payable (Days)	549	1029	518	343	311	304	304	304	304	304	304	304	304
Book & Cash Value (per share)													
Book Value per Share (diluted)	(10.09)	(8.48)	(9.62)	1.23	1.21	0.85	0.34	0.19	0.07	(0.04)	(0.14)	(0.22)	(0.30)
Cash per Share (diluted)	0.11	0.01	0.01	0.42	0.54	0.43	0.10	(0.05)	(0.17)	(0.28)	(0.38)	(0.46)	(0.53)
Net cash per Share (diluted)	(9.34)	(10.59)	(11.09)	0.39	0.50	0.41	0.09	(0.06)	(0.19)	(0.30)	(0.39)	(0.47)	(0.55)

Source: Company reports, Ascendant Capital Markets estimates

60 Degrees Pharmaceuticals, Inc.

Cash Flow Statement (\$ mils)	2022	Mar-23	Jun-23	Sep-23	Dec-23	2023	Mar-24	Jun-24	Sep-24	Dec-24	2024	Mar-25	Jun-25	Sep-25	Dec-25	2025
Fiscal Year End: December 31	FY-A	Q1A	Q2A	Q3A	Q4A	FY-A	Q1E	Q2E	Q3E	Q4E	FY-E	Q1E	Q2E	Q3E	Q4E	FY-E
Net Income	(6.2)	(2.6)	(3.3)	4.2	(2.0)	(3.8)	(1.4)	(1.6)	(1.6)	(1.4)	(6.0)	(1.2)	(1.1)	(0.9)	(0.9)	(4.5)
Adjustments to Net Income																
Depreciation	0.0		0.0	0.0	0.0	0.0										
Amortization	0.0	0.3	0.6	(0.9)	0.0	0.0										
Amortization of Debt Discount	1.1	0.3		0.3	0.0	0.7										
Amortization of ROU Asset	0.0	0.0		0.0	0.0	0.1										
Amortization of Note Issuance Costs	0.1	0.0		0.0	0.0	1.0										
Amortization of Capitalized Services				0.7	0.3	1.0										
Stock-based Compensation to Vendors for services				0.7	(0.5)	0.2										
Stock-based Compensation under 2022 Equity Incentive Plan					0.5289	0.5										
Deemed Capital Contribution for Related Party Compensation Expense						0.2										
Gain on Debt Extinguishment	(0.1)			1.2	0.0	1.2										
Change in Fair Value of Derivative Liabil	0.0			(0.1)	0.1	0.0										
Derivative Expense	0.5			0.4	0.0	0.4										
Change in Fair Value of Promissory Note				(5.4)	0.0	(5.4)										
Inventory Reserve	0.2			(0.1)	(0.0)	(0.2)										
Changes in Operating Assets and Liabilities																
Change in Acc. Receivable	0.1	(0.0)	(0.0)	(0.8)	0.7	(0.2)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaid and Other	0.0	0.0		(1.5)	1.0	(0.5)										
Change in Inventories	(0.1)	(0.1)	0.1	0.1	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Change in Inventory Reserves					(0.0)											
Change in Acc. Payable	0.2	0.1	0.2	(0.8)	0.3	(0.2)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accrued Interest	2.7	0.8		0.5	(0.0)	1.3					0.0					
Reduction of Lease Liability	(0.0)	(0.0)		(0.0)	(0.0)	(0.1)					0.0					
Deferred Compensation	0.4	0.0	0.6	(0.7)	0.0	(0.1)					0.0					
Stock based Compensation		0.2	0.1	(0.3)	0.0	0.0					0.0					
Gain on Debt Extinguishment		0.8														
Change in Fair Value of Derivatives Liability		0.0														
Change in Fair Value of Promissory Notes		(0.3)														
Other Operating Activities			1.5	(1.2)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net cash used in operating activities	(1.0)	(0.4)	(0.3)	(3.7)	0.8	(4.5)	(1.4)	(1.6)	(1.6)	(1.4)	(6.0)	(1.2)	(1.1)	(0.9)	(0.9)	(4.5)
Capitalization of Patents	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)					0.0					
Purchase of PP&E				(0.0)	(0.1)	(0.1)										
Sale (Purchase) of Intangible assets	(0.0)			(0.0)	0.0	(0.0)										
Net cash used in investing activities	(0.1)	(0.0)	(0.0)	(0.0)	(0.1)	(0.1)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Proceeds from Stock Offering				6.5	0.0	6.5	2.0				2.0					
Payment of Deferred Offering Costs	(0.1)	(0.0)	(0.1)	(0.0)	(0.0)	(0.2)										
Proceeds from Exercise of Warrants				1.1	0.0	1.1										
Proceeds from Notes Payable	0.8			0.7	0.0	0.7										
Repayment of Notes Payable				(1.6)	0.0	(1.6)										
Proceeds from Notes Payable - Related f	0.3	0.2	0.7	(0.9)	0.0	0.0										
Repayments on Notes Payable - Related Parties			(0.3)		0.0	(0.3)										
Proceeds from Advances - Related Party	0.2			0.3	0.0	0.3										
Net cash provided by financing activities	1.2	0.2	0.3	6.0	(0.0)	6.5	2.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0
Foreign Exchange Rate Adj.	(0.0)	(0.0)	(0.0)	0.0	0.1	0.1										
Net Change in Cash	0.1	(0.2)	(0.0)	2.2	(0.1)	1.9	0.6	(1.6)	(1.6)	(1.4)	(4.0)	(1.2)	(1.1)	(0.9)	(0.9)	(4.5)
Cash balance at beginning of period	0.1	0.3	0.0	0.0	2.2	0.3	2.1	2.7	1.1	(0.5)	2.1	(1.9)	(3.1)	(4.2)	(5.1)	(1.9)
Cash balance at end of period	0.3	0.0	0.0	2.2	2.1	2.1	2.7	1.1	(0.5)	(1.9)	(1.9)	(3.1)	(4.2)	(5.1)	(5.9)	(6.4)

Source: Company reports, Ascendant Capital Markets estimates

ANALYST CERTIFICATION

Each analyst hereby certifies that the views expressed in this report reflect the analyst's personal views about the subject securities or issuers. Each analyst also certifies that no part of the analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. The analyst who prepared this report is compensated based upon the overall profitability of Ascendant Capital Markets, LLC, which may, from time to time, include the provision of investment banking, financial advisory and consulting services. Compensation for research is based on effectiveness in generating new ideas for clients, performance of recommendations, accuracy of earnings estimates, and service to clients.

60 Degrees Pharmaceuticals, Inc.

- Ascendant Capital Markets, LLC has received compensation for advisory or investment banking services from the company in the past 12 months.

IMPORTANT DISCLOSURES

This report has been distributed by Ascendant Capital Markets, LLC and is for the sole use of our clients. This report is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. This report contains information from various sources, including United States government publications, The Wall Street Journal and other periodicals, Yahoo! Finance and other sources, and is for informational purposes only and is not a recommendation to trade in the securities of the companies mentioned within the report. We seek to update our research and recommendations as appropriate, but the large majority of reports are published at irregular intervals as we consider appropriate and, in some cases, as constrained by industry regulations.

We may have a business relationship with companies covered in this report. Ascendant Capital Markets, LLC may make a market in the securities of the subject company. We and our affiliates, officers, directors, and employees will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this report. This report is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any information in this report is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of the investments referred to in this report may fluctuate.

Following are some general risks that can adversely impact future operational and financial performance and share price valuation: (1) industry fundamentals with respect to legislation, mandates, incentives, customer demand, or product pricing; (2) issues relating to competing companies or products; (3) unforeseen developments with respect to management, financial condition or accounting policies or practices; or (4) external factors that affect the interest rates, currency, the economy or major segments of the economy. Past performance is not a guide to future performance, future returns are not guaranteed, and loss of original capital may occur. Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Our report is disseminated primarily electronically, and, in some cases, in printed form. The information contained in this report is not incorporated into the contents of our website and should be read independently thereof. Copyright Ascendant Capital Markets, LLC. No part of this material may be copied, photocopied or duplicated by any means or redistributed without the prior written consent of Ascendant Capital Markets, LLC.

Risks & Considerations

Risks to attainment of our share price target include balance sheet/liquidity risks, failure of product candidates to demonstrate safety and efficacy in clinical trials, failure to gain regulatory approvals, ability to commercialize product, failure to obtain suitable reimbursement, competition, changing macroeconomic factors, investor sentiment for investing in healthcare stocks, and changes in consumer or government priorities for healthcare.

Ascendant Capital Markets, LLC Rating System

BUY: We expect the stock to provide a total return of 15% or more within a 12-month period.

HOLD: We expect the stock to provide a total return of negative 15% to positive 15% within a 12-month period.

SELL: We expect the stock to have a negative total return of more than 15% within a 12-month period.

Total return is defined as price appreciation plus dividend yield.

Ascendant Capital Markets, LLC Distribution of Investment Ratings (as of January 15, 2024)

Rating	Count	Percent	Investment Banking Services Past 12 months	
			Count	Percent
Buy	52	98%	20	38%
Hold	0	0%	0	0%
Sell	1	2%	0	0%
Total	53	100%	16	38%

Other Important Disclosures

Our analysts use various valuation methodologies including discounted cash flow, price/earnings (P/E), enterprise value/EBITDAS, and P/E to growth rate, among others. Risks to our price targets include failure to achieve financial results, product risk, regulatory risk, general market conditions, and the risk of a change in economic conditions.

Dissemination of Research

Ascendant Capital Markets, LLC research is distributed electronically via the Thomson Reuters platforms, Bloomberg, Capital IQ, and FactSet. Please contact your investment advisor or institutional salesperson for more information.

General Disclaimer

The information and opinions in this report were prepared by Ascendant Capital Markets, LLC. This information is not intended to be used as the primary basis of investment decisions and because of individual client objectives it should not be construed as advice designed to meet the particular investment needs of any investor. This material is for information purposes only and is not an offer or solicitation with respect to the purchase or sale of any security. The reader should assume that Ascendant Capital Markets, LLC may have a conflict of interest and should not rely solely on this report in evaluating whether or not to buy or sell securities of issuers discussed herein. The opinions, estimates, and projections contained in this report are those of Ascendant Capital Markets, LLC as of the date of this report and are subject to change without notice. Ascendant Capital Markets, LLC endeavors to ensure that the contents have been compiled or derived from sources that we believe are reliable and contain information and opinions that are accurate and complete. However, Ascendant Capital Markets, LLC makes no representation or warranty, express or implied, in respect thereof, takes no responsibility for any errors and omissions contained herein, and accepts no liability whatsoever for any loss arising from any use of, or reliance on, this report or its contents. Information may be available to Ascendant Capital Markets, LLC, or its affiliates that is not reflected in this report. This report is not to be construed as an offer or solicitation to buy or sell any security.

Additional Disclosures

Ascendant Capital Markets, LLC is a broker-dealer registered with the United States Securities and Exchange Commission (SEC) and a member of the FINRA and SIPC. Ascendant Capital Markets, LLC is not a Registered Investment Advisor nor is it an investment advisor registered with the Securities and Exchange Commission or with the securities regulators of any state, and at the present time is not eligible to file for federal registration.